Maxygen (MAXY)
Maxygen Revenue Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MAXY Revenue Growth Range, Past 5 Years
| Minimum | -99.43% | Dec 2011 |
| Maximum | 9085% | Sep 2008 |
| Average | 576.6% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these MAXY related companies
MAXY News
BMC Software, The Ultimate Software Group Included in Stocks Up on High Volume Monday
May 14, 12:33PM Fox Business
May 14, 12:33PM Fox Business
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
$MAXY forms bullish "Continuation Wedge" chart pattern. http://stks.co/3OAl
about 39 days ago by RecogniaEvents
about 39 days ago by RecogniaEvents
$MAXY http://stks.co/29DH vol laden nr7 friday w/ pos hard sell below $5.4
about 117 days ago by traderdigs
about 117 days ago by traderdigs
Maxygen Announces BARDA Decision Not To Award Contract for Development of MAXY-G34 for Acute Radiation Syndrome
Nov 09, 4:30PM Business Wire
Nov 09, 4:30PM Business Wire
$MAXY set to rally after breaking out of long consolidation rectangle. Looks to close the December 2010 gap at $6.80
about 228 days ago by checkthetechs
about 228 days ago by checkthetechs
Maxygen announces final rejection of '804 patent in inter partes reexamination
Oct 10, 5:17PM FlyOnTheWall
Oct 10, 5:17PM FlyOnTheWall
Maxygen Announces Final Rejection of All Claims of Amgen ‘804 Patent in Inter Partes Reexamination Proceeding
Oct 10, 5:00PM Business Wire
Oct 10, 5:00PM Business Wire
Some Swings and Scalps for Today: $RCKB $IPAS $MAXY $DGII http://stk.ly/keEf56
about 344 days ago by SharePlanner
about 344 days ago by SharePlanner
=> $MAXY $5.23 LEE KENNETH B JR director P 3,000 @ $5.23 amnt $15,690 proc'd $0 6/1/2011
about 360 days ago by canarionyc
about 360 days ago by canarionyc
$MAXY--Director purchased 20,000 shares at $5.16. Last trade is $5.08. Nice float, decent avg volume. Do your own research.
about 369 days ago by MicroInsider
about 369 days ago by MicroInsider
$MAXY $5.08 STEIN ISAAC director P 20,000 @ $5.16 amnt $103,200 proc'd ($1,600) 5/19/2011
about 372 days ago by canarionyc
about 372 days ago by canarionyc
$MAXY tries for radiation exposure BARDA award w/ MAXY-34: http://stk.ly/jd0fhC Didn't a Canadian licensee already fail with this attempt?
about 388 days ago by BioDueDiligence
about 388 days ago by BioDueDiligence
$MAXY http://chart.ly/xbp2y4t Spec biotech showing tight weekly closes after big move; like to see this - good support
about 416 days ago by Kenshreve
about 416 days ago by Kenshreve
Astellas exercises option to buy out $MAXY JV for 76m http://stk.ly/egeX5B Nice deal, but makes the 20m deal w/ $CDXS look even worse
about 436 days ago by BioDueDiligence
about 436 days ago by BioDueDiligence
$MAXY 4q2010 results: http://stk.ly/dQTWE9 Does this structure and strategy make sense to anyone besides the 5 guys still getting paychecks?
about 444 days ago by BioDueDiligence
about 444 days ago by BioDueDiligence
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MAXY | 5.85 | +0.02 | +0.34% | 162.45M |
| MAR | 38.64 | +0.25 | +0.65% | 12.90B |
| MA | 413.96 | -5.87 | -1.40% | 52.37B |
| LZB | 14.34 | +0.05 | +0.35% | 743.67M |
| LXRX | 1.60 | +0.00 | +0.00% | 768.90M |
| LXP | 8.39 | -0.03 | -0.36% | 1.304B |
| LVS | 47.92 | +0.00 | +0.00% | 35.18B |
| LVLT | 21.99 | -0.48 | -2.14% | 4.753B |
| LUV | 8.76 | +0.02 | +0.23% | 6.771B |
| LUNA | 1.62 | -0.03 | -1.87% | 22.36M |
